Molecular Pathology/Genetic Testing Reported with Unlisted Codes | UHC Coverage Update

TL;DR: UnitedHealthcare modified its molecular pathology and genetic testing unlisted codes coverage policy, effective February 2, 2026. Here's what changes for billing teams.

This update affects how UnitedHealthcare — operating as UnitedHealthcare across its Medicare Advantage plans — covers claims submitted under CPT 81479, CPT 81599, and CPT 84999. These three unlisted codes are the fallback codes your team uses when no specific molecular pathology code exists. The policy tightens the criteria for what counts as reasonable and necessary, layers in CMS NCD and LCD compliance requirements, and spells out specific oncology biomarker indications that are covered — and several that aren't.

Quick-Reference Table

UnitedHealthcare Molecular Pathology Unlisted Code Coverage Criteria and Medical Necessity Requirements 2026

The core rule here is straightforward: unlisted codes like CPT 81479, 81599, and 84999 should only appear on a claim when no specific code exists for the test performed. If a specific CPT code exists — and in molecular pathology, many do — using an unlisted code instead is a fast path to a claim denial.

UnitedHealthcare's coverage policy requires that any service billed under these unlisted codes meet the standard CMS definition of reasonable and necessary under Social Security Act §1862(a)(1)(A). That means the test must be safe and effective, not experimental or investigational, and appropriate for the patient's condition. It also must be ordered by qualified personnel, performed in the right setting, and not exceed the patient's medical need.

The policy also explicitly requires compliance with CMS NCD 90.2 — the National Coverage Determination governing Next Generation Sequencing — wherever it applies. Local Coverage Determinations and Local Coverage Articles from the relevant Medicare Administrative Contractor also govern. If your patient is in a state or territory without an applicable LCD, the policy's own coverage rationale section controls. Check the Medicare Coverage Database to confirm which LCD applies to your billing jurisdiction before submitting claims.

When your team submits a claim under CPT 81479, 81599, or 84999, the specific name of the laboratory test — or at minimum a short descriptor — must be included on the claim. This is not optional. Missing test names are a primary driver of claim denial under this policy. Build that into your charge capture workflow now.

Prior authorization requirements for specific tests under this molecular pathology genetic testing coverage policy are not uniformly spelled out in this document, but given the high-cost nature of these tests and UnitedHealthcare's broader Medicare Advantage prior auth practices, confirm current prior authorization requirements for any test you're considering billing under these codes. Talk to your compliance officer if you're unsure which tests trigger prior auth for your MA plan population.

UnitedHealthcare Molecular Pathology Unlisted Code Exclusions and Non-Covered Indications

Several tests listed in the policy are explicitly non-covered or restricted. The Rosetta Cancer Origin Test (PROG) is covered only for cancer of unknown primary when conventional surgical pathology and imaging can't identify the primary site. Using it for specific tumor typing — Non-Small Cell Lung Cancer or renal cancers — is not covered. UnitedHealthcare considers those applications investigational.

The MyPRS Genetic Expression Profile test for multiple myeloma is another one to watch. It's covered only after an initial multiple myeloma diagnosis, and only for therapeutic stratification. Using it as a diagnostic tool is explicitly not covered. Using it to monitor ongoing therapy is also not covered — other tests exist for that function, and UnitedHealthcare will not reimburse MyPRS for monitoring purposes.

The RosettaGX Reveal thyroid MicroRNA test is covered as an assay for classifying indeterminate thyroid nodules. No other applications are listed as covered.

If your lab or practice has been billing CPT 81479 broadly across these tests without confirming the specific indication, this policy creates real financial exposure. Reimbursement for claims that don't match the covered indications listed in the policy will not follow — denials will.

Coverage Indications at a Glance

UnitedHealthcare Molecular Pathology Genetic Testing Billing Guidelines and Action Items 2026

These are the specific steps your billing team needs to take before and after the February 2, 2026 effective date.

CPT, HCPCS, and ICD-10 Codes for Molecular Pathology Unlisted Procedures Under molecular-path-genetic-test-unlisted-codes

Covered CPT Codes (When Medical Necessity and Selection Criteria Are Met)

These three codes are covered only when no specific CPT code exists for the test performed, the test meets medical necessity criteria under §1862(a)(1)(A), and the claim includes the specific test name or descriptor.

Key ICD-10-CM Diagnosis Code Notes

The policy references a Non-Covered Diagnosis Codes List — a list of ICD-10-CM codes that will never support coverage when listed as the primary diagnosis on a claim. The full list is contained in the policy's applicable codes section. Pull that list from the source policy document and cross-reference it against your charge capture to prevent automatic denials. If you don't have access to the full list, request it from your UHC provider relations contact or retrieve it directly from the policy at PayerPolicy.